Drug Profile
Linoleyl carbonate-paclitaxel conjugate - American Regent
Alternative Names: 2-linoleyl carbonate-paclitaxel; LOC-pac; LOC-paclitaxelLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Luitpold Pharmaceuticals
- Developer Luitpold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 02 Jan 2019 Luitpold Pharmaceuticals is now called American Regent
- 28 Dec 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Metastatic disease) in USA (IV, Infusion)
- 01 Feb 2016 Luitpold Pharmaceuticals terminates a phase I trial in Malignant melanoma (Metastatic disease, Second-line therapy or greater) in USA due to early positive results (NCT01039844)